Instrument Inactif

Autres langues Loxo Oncology Inc

Actions

US5488621013

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Loxo Oncology : Merus Enters Collaboration With Eli Lilly To Develop New Generation Of Cancer Treatments	05/02/21
Eli Lilly and : Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma	08/12/20
Eli Lilly and : Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting	09/12/19
Bayer : gains full Vitrakvi rights from Eli Lilly's Loxo	15/02/19
Loxo Oncology : Lilly Completes Acquisition of Loxo Oncology	15/02/19
Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction	01/02/19
GlaxoSmithKline : to look for early-stage assets - CEO	08/01/19
Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy	07/01/19
Amazon and Netflix push Wall Street higher	07/01/19
Bayer : Eli Lilly treibt Konsolidierung der Pharmabranche mit Zukauf an	07/01/19
Lilly Announces Agreement To Acquire Loxo Oncology	07/01/19
Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305	21/12/18
Bayer : Lower drug sales potential at Bayer underscores need for deals	05/12/18
Bayer : Lower drug sales potential at Bayer underscores need for deals	05/12/18
Bayer : US-Gesundheitsbehörde lässt neues Krebsmittel von Bayer zu	27/11/18
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)	27/11/18
Bayer : Roche takes on Loxo, Bayer in gene-defined cancer class	21/10/18
Loxo Oncology : Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types	21/10/18
Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress	21/10/18
Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer	15/10/18

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Loxo Oncology Inc

Actions

US5488621013

Autres langues

Filtres